Announcements Trials
Browse Landscape

Phase

Phase 2 64Phase 1 25Phase 1/2 16Phase NA 14Phase 3 14Phase EARLY_PHASE1 4Phase 2/3 4Phase 4 1

Status

Completed 10Recruiting 8Terminated 6Unknown 5Not yet recruiting 4Active not recruiting 4Withdrawn 3

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Prostatic Neoplasms 10Glioma 9Glioblastoma 8Sarcoma 7Pancreatic Neoplasms 6Neoplasms 6Neoplasm Metastasis 6Brain Neoplasms 5Recurrence 4Neuroendocrine Tumors 4Neuroblastoma 4Lymphoma 4Lung Neoplasms 4Head and Neck Neoplasms 4Colonic Neoplasms 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Multiple Myeloma 3Melanoma 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Smoldering Multiple Myeloma 2Smoking Cessation 2Smoking 2Skin Neoplasms 2Sarcoma, Alveolar Soft Part 2

Interventions

pembrolizumab 1fludarabine phosphate 1fludarabine 1brexucabtagene autoleucel 1acalabrutinib 1Simvastatin 1Rituximab 1Dexamethasone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Active not recruiting × Lymphoma × Clear all
NCT05651178 2026-06-04

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Hrain Biotechnology Co., Ltd.

Phase EARLY_PHASE1 Active not recruiting
10 enrolled
Lymphoid

Lymphoma, Recurrence

NCT04541108 2026-05-22

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Presage Biosciences

Phase EARLY_PHASE1 Active not recruiting
15 enrolled
DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT05495464 2026-05-20

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT04514029 2026-01-08

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

Masonic Cancer Center, University of Minnesota

Phase EARLY_PHASE1 Active not recruiting
37 enrolled
Lymphoid

Lymphoma, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡